| Name | Title | Contact Details |
|---|
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
Orphan Star Therapeutics, LLC, a biopharmaceutical company, develops therapies for rare genetic diseases including Canavan disease, glut1 deficiency, and rare genetic skin diseases.
SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.
Preferred Health Partners is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.